Regencell Bioscience Holdings Limited (RGC)
NASDAQ: RGCHealth Care Medicinal Chemicals and Botanical Products USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
RGC stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.07B
- EPS (TTM)
- -$0.02
- Dividend yield
- None
- 52-week range
- 4.12 – 69.00
- Day range
- 4.12 – 4.43
- Volume / Avg
- 110.89K / 234.51K
- Beta
- —
- Shares outstanding
- 495.88M
52-week range
RGC stock today
Shares of Regencell Bioscience (RGC) finished lower on Nov 20 at $4.18, a drop of 4.13% or $0.18 per share, versus the S&P 500's 3.70% decline. Trading was light, with 110.89K shares changing hands, about 47% of the average daily volume. At this level, RGC sits near the bottom of its 52-week range of $4.12 to $69.00: 93.9% below the high, set on Jan 8, 2026 and 1.5% above the low.
RGC is down 80.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 66.5%. Regencell Bioscience has posted a net loss over the last twelve months (EPS of -$0.02), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Regencell Bioscience
Company profileRegencell Bioscience Holdings Limited focuses on the research, development, and commercialization of Traditional Chinese Medicine (TCM) in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, TCM brain theory, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
- Sector
- Health Care
- Industry
- Medicinal Chemicals and Botanical Products
- CEO
- Mr. Yat-Gai Au
- Headquarters
- Causeway Bay
- Employees
- 10
- IPO year
- 2021
- Website
- regencellbioscience.com
Financial highlights
Full financialsRegencell Bioscience reported a net loss of $11.7 million, compared with a loss of $3.6 million a year earlier. Diluted earnings per share came in at -$2.37.
| Fiscal year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-11.70M | $-3.58M | $-4.30M | $-5.87M | $-7.45M |
| EPS (diluted) | $-2.37 | $-0.72 | $-0.87 | $-1.19 | $-0.58 |
RGC news
All RGC newsRegencell Bioscience peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| TRLVTrulieve Cannabis Corp. Subordinate Voting Shares | 8.68 | -7.17% | $1.48B | vs RGC |
| CRONCronos Group Inc. | 3.04 | -1.30% | $1.11B | vs RGC |
| OBIOOrchestra BioMed Holdings Inc. | 6.58 | -6.00% | $517.88M | vs RGC |
| SNDLSNDL Inc. | 1.17 | -5.65% | $285.20M | vs RGC |
| TLRYTilray Brands Inc. | 1.89 | -8.70% | $279.32M | vs RGC |
| ACBAurora Cannabis Inc. | 4.16 | -2.35% | $273.50M | vs RGC |
| DFTXDefinium Therapeutics Inc. | 28.34 | -3.87% | $3.88B | vs RGC |
| USNAUSANA Health Sciences Inc. | 12.94 | -1.67% | $239.24M | vs RGC |
Indexes, lists and sector
Regencell Bioscience stock FAQ
What is Regencell Bioscience's stock price today?
RGC last traded at $4.18 as of Nov 20, 4:00 PM EST, down 4.13% on the day. Prices are delayed at least 15 minutes.
Does Regencell Bioscience pay a dividend?
No. Regencell Bioscience does not currently pay a regular cash dividend.
Who is Regencell Bioscience's CEO?
Mr. Yat-Gai Au is the chief executive officer of Regencell Bioscience Holdings Limited, which has about 10 employees.
Has RGC ever split its stock?
Yes. The most recent RGC stock split was a 38-for-1 split on Jun 16, 2025.
What is the RGC 52-week high?
The 52-week high for RGC is $69.00 and the 52-week low is $4.12. The stock is currently 93.9% below its high.